Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289622 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL14940213 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL14134967 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL10087481 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TDP1 | |
| SCHEMBL24240747 | 0.78 | — | — | |
| SCHEMBL12942702 | 0.78 | — | — | |
| SCHEMBL10330335 | 0.78 | — | — | |
| SCHEMBL10033827 | 0.78 | — | — | |
| SCHEMBL21323889 | 0.78 | — | — | |
| SCHEMBL12951886 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209001-A1 | 2-Deoxy-D-Ribose 5-Phosphate Aldolases (DERAS) And Uses Thereof | DSM IP ASSET B.V. (NL) | 2009-08-20 | — | — | US | claimed |
| EP-1751287-A2 | IMPROVED 2-DEOXY-D-RIBOSE 5-PHOSPHATE ALDOLASES (DERAS) AND THE USES THEREOF | DSMIP Assets B.V. (NL) | 2007-02-14 | — | — | EP | claimed |
| WO-2005118794-A2 | IMPROVED 2-DEOXY-D-RIBOSE 5-PHOSPHATE ALDOLASES (DERAS) AND THE USES THEREOF | DSM IP ASSETS B.V. (NL) | 2005-12-15 | — | — | WO | claimed |
| US-8148324-B2 | Aldolases, nucleic acids encoding them; improving thermal stability of enzyme; biosynthesis of atorvastatin, rosuvastatin, fluvastatin starting from e.g. acetaldehyde and chloroacetaldehyde, using enzyme 2-deoxyribose-5-phosphate aldolase (DERA) to form pyran intermediate | VERENIUM CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090209001-A1 | 2-Deoxy-D-Ribose 5-Phosphate Aldolases (DERAS) And Uses Thereof | DSM IP ASSET B.V. (NL) | 2009-08-20 | — | — | US | disclosed |
| US-20090209001-A1 | 2-Deoxy-D-Ribose 5-Phosphate Aldolases (DERAS) And Uses Thereof | DSM IP ASSET B.V. (NL) | 2009-08-20 | — | — | US | disclosed |
| US-20080289056-A1 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES | VERENIUM CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1751287-A2 | IMPROVED 2-DEOXY-D-RIBOSE 5-PHOSPHATE ALDOLASES (DERAS) AND THE USES THEREOF | DSMIP Assets B.V. (NL) | 2007-02-14 | — | — | EP | disclosed |
| EP-1751287-A2 | IMPROVED 2-DEOXY-D-RIBOSE 5-PHOSPHATE ALDOLASES (DERAS) AND THE USES THEREOF | DSMIP Assets B.V. (NL) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118794-A3 | IMPROVED 2-DEOXY-D-RIBOSE 5-PHOSPHATE ALDOLASES (DERAS) AND THE USES THEREOF | DSM IP ASSETS BV (NL) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005118794-A2 | IMPROVED 2-DEOXY-D-RIBOSE 5-PHOSPHATE ALDOLASES (DERAS) AND THE USES THEREOF | DSM IP ASSETS B.V. (NL) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118794-A2 | IMPROVED 2-DEOXY-D-RIBOSE 5-PHOSPHATE ALDOLASES (DERAS) AND THE USES THEREOF | DSM IP ASSETS B.V. (NL) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209001-A1 | 2-Deoxy-D-Ribose 5-Phosphate Aldolases (DERAS) And Uses Thereof | DERA, ALDOA, RPIA | ALDH1A1 262/4885TDP1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.